Abstract:OBJECTIVE To evaluate the dosing regimens of levofloxacin. METHODS The drug concentrations in serum and urine were assayed by HPLC method and the pharmacokinetic parameters were calculated after intravenous infusion of a single dose of 200 mg, 300 mg and 500 mg levofloxacin to healthy volunteers. The in vitro activity MIC of levofloxacin against 823 clinical isolates were determined and compared with other antimicrobial agents. Based on the above results, the PK/PD parameters C(max)/MIC and AUC/MIC were calculated and the dosing regimens of levofloxacin were proposed for infections caused by different pathogens. RESULTS The results of clinical pharmacokinetic study showed that the C(max) of levofloxacin was 3.4 mg/L +/- 0.8 mg/L, 4.8 mg/L +/- 1.4 mg/L and 7.6 mg/L +/- 1.1 mg/L respectively, AUC(0-infinity) was 14.4 mg.h/L +/- 2.5 mg.h/L, 21.9 mg.h/L +/- 4.5 mg.h/L and 38.3 mg.h/L +/- 4.9 mg.h/L respectively, T(1)/2 beta was 6.2 h +/- 0.4 h, 6.4 h +/- 0.9 h and 6.5 h +/- 0.6 h respectively, and 69% +/- 5%, 69% +/- 6%, and 65% +/- 4% of the doses were excreted in urine within 24 h after intravenous infusion of a single dose of levofloxacin 200 mg, 300 mg and 500 mg. The in vitro pharmacodynamic study showed that levofloxacin was highly active against Hemolytic streptococcus and Moraxella catarrhalis. It was active against Streptococcus pneumoniae (including penicillin nonsusceptible strains), Hemophilus influenzae, methicillin-sensitive Staphylococcus aureus (MSSA), Klebsiella pneumoniae and Stenotrophomonas maltophilia. Levofloxacin also had good activity against Pseudomonas aeruginosa and K.pneumoniae. However, most of isolates of enterococcal spp. were resistant to levofloxacin. Above 50% of Escherichia coli isolates were resistant to levofloxacin. Based on the results of PK/PD parameters, the adequate dosing regimens of levofloxacin should be once daily 200 mg once daily of levofloxacin was expected to be effective for the treatment of infections caused by M. catarrhalis. The regimen of 300 mg once daily could be effective for the treatment of infections caused by Hemolytic streptococcus. 500 mg once daily of levofloxacin was expected to be effective for the treatment of respiratory tract infections caused by S. pneumoniae or H. influenzae. For treatment of respiratory tract infections and urinary tract infections caused by levofloxacin-susceptible organisms including K. pneumoniae, E. coli, P. aeruginosa, and S.maltophilia, 500 mg once daily of levofloxacin was needed to obtain good clinical efficacy. But PK/PD parameters predicted that 500 mg daily of levofloxacin was not effective for infections caused by methicillin-resistant Staphylococcus aureus (MRSA) and Enterococci. CONCLUSION The proposed dosing regimens of levofloxacin based on PK/PD concepts are expected to provide good efficacy in clinical practice.

Pharmacokinetics of Levofloxacin in Rat Pancreas

Quantitative Determination of Unbound Levofloxacin by Simultaneous Microdialysis in Rat Pancreas after Intravenous and Oral Doses

Chronopharmacokinetics Study of Levofloxacin in Rats

Study on Pharmacokinetics of Levofloxaein Hydrochloride in Pathological Model of Rats with Bacterial Prostatitis

PHARMACOKINETICS AND BIOAVAILABILITY OF CLINAFLOXACIN IN RATS

Pharmacokinetics of Levofloxacin after a Single Intravenous Administration in Human

Pharmacokinetics of Levofloxacin in Chickens after Oral Administration

Determination of Antofloxacin in Rat Plasma and Bile by HPLC and Study of Its Pharmacokineics

Pharmacokinetics of a Single Oral Administration of Levofloxacin in Piglets with Indigestion

Pharmacokinetics of levofloxacin in patients with pneumonia

Effects of levofloxacin on the plasma concentration of baicalin in rats

HPLC Assay of Levofloxacin in Human Plasma and Its Relative Bioavailability

Absolute bioavailability of levofloxacin tablet in healthy Chinese male subjects

[Study of Pharmacokinetics/pharmacodynamics of Levofloxacin].

Pharmacokinetics of Levofloxacin Hydrochloride Soft Capsules, Hard Capsules and Tablets in Chinese Healthy Volunteers

DETERMINATION OF CEFOTAXIME SODIUM IN RAT'S PANCREAS BY RP-HPLC

Pharmacokinetic Study of Aesculin and Aesculetin in Rats

Concentration of panaxynol in rat plasma determined by high performance liquid chromatography and its pharmacokinetic study

Dissolution in vitro and pharmacokinetics of levofloxacin hydrochloride sustained-release tablets

Study on pharmacokinetics of pazopanib in rats

Pharmacokinetics of gatifloxacin mesylate and gatifloxacin in rats in vivo